Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.
暂无分享,去创建一个
M. Sadelain | A. Quintás-Cardama | R. Brentjens | I. Rivière | Raymond Yeh | D. Hollyman | J. Stefanski | Clare Taylor | Yan Nikhamin | G. Imperato | A. Quintás-Cardama
[1] S. Larson,et al. Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.
[2] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[3] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[4] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[5] A. Zander,et al. Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] D. Klatzmann,et al. Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. , 2000, Human gene therapy.
[7] A. Zander,et al. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements , 1999, Gene Therapy.
[8] David A. Williams,et al. High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments , 1998, Journal of Virology.
[9] C. Bordignon,et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.
[10] R. Mulligan,et al. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] David A. Williams,et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.
[12] S. Rosenberg,et al. T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.
[13] Evelina Mazzolari,et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.
[14] R. Morgan,et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Mulligan,et al. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] W. Anderson,et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. , 1993, Journal of immunology.
[17] K. Cornetta,et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Miller,et al. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.
[19] W. Anderson,et al. Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent , 1989, Journal of virology.
[20] M. Sadelain,et al. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories , 2006, Gene Therapy.
[21] S. Sleijfer,et al. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. , 2006, Cytotherapy.
[22] Michel Sadelain,et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.
[23] J. Segovia,et al. Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells , 2001, The journal of gene medicine.
[24] M. Yamada,et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. , 1998, Blood.
[25] W F Anderson,et al. Improved methods of retroviral vector transduction and production for gene therapy. , 1994, Human gene therapy.